Salvage chemotherapy in relapsed germ cell tumors

World Journal of Urology

Volumn 19, Issue 2, 2001, Pages 90-93

  Beyer, J ^a   Rick, O ^b   Siegert, W ^b   Bokemeyer, C ^c  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Germ cell tumor; Prognosis; Recurrence; Salvage therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; ICE PROTOCOL 1; IFOSFAMIDE; PACLITAXEL; TAXOID; TIP REGIMEN; VEIP PROTOCOL; VINBLASTINE;

GERM CELL TUMOR; HUMAN; MALE; REVIEW; TESTIS TUMOR; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; ETOPOSIDE; GERMINOMA; HUMANS; IFOSFAMIDE; MALE; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TAXOIDS; TESTICULAR NEOPLASMS; VINBLASTINE;

EID: 0035318181     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00007095     Document Type: Article

References (20)

1. Baniel J, Forster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LE (1995) Late relapse of testicular cancer. J Clin Oncol 13: 1170-1176
2. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W (1994) Treatment intensification in disseminated germ-cell tumors. World J Urol 12: 207-213
3. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, Pico JL, Diehl A, Bokemeyer C, Schmoll HJ, Nichols CR, Einhorn LH, Siegert W (1996) High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic factors. J Clin Oncol 14: 2638-2645
4. Beyer J, Stenning S, Gerl A, Fossa S, Siegert W (1999) Highdose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. Proc Am Soc Clin Oncol 18: 1255
5. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weissbach L, Köhrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31 -34
6. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999) First-line high-dose chemotherapy compared with standard-dose PEB/'VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol 17: 3450-3456
7. Bosl G, Motzer RJ (1997) Testicular germ-cell cancer. N Engl J Med 337: 242-253
8. Fossa SD, Stenning SP, Gerl A, Horwich A, Clark PI, Wilkinson PM, Jones WG, Williams MV, Oliver RT, Newlands ES, Mead GM, Cullen MH, Kaye SB, Rustin GJS. Cook PA (1999) Prognostic factors in patients progressing after platinum-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 80: 1392 1399
9. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603
10. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540-546
11. Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH ( 1998) Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504
12. Miller KD, Loehrer PJ, Gonin R, Einhorn LH (1997) Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma. J Clin Oncol 15: 1427-1431
13. Motzer RB, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, Bajorin D, Bosl GJ (2000) Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 18: 2413 -2418
14. Motzer RJ, Mazumdar M, Sheinfeld J, Bajorin DF, Macapinlac HA, Bains M, Reich L, Flombaum C, Mariani T, Tong WP, Bosl GJ (2000) Sequential dose-intensive paclitaxel, ifosfamide, carboplatin and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 18: 1173 1180
15. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, Einhorn LH (1993) Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 11: 324 329
16. Rick O, Siegert W, Beyer J (1999) High-dose salvage chemotherapy. Germ-cell tumor treatment results in Germany. Int J Cancer 83: 839-840
17. Rick O, Bokemeyer C, Beyer J, Hartmann JT, Schwella N. Kingreen D, Neureither S, Metzner B, Casper J, Wandt H, Hartmann F, Schmoll HJ, Derigs G. Gerl A, Berdel WE, Kanz L, Siegert W (2001) Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 19: 81-88
18. Rodenhuis S, de Wit R, de Mulder PHM, Keizer HJ, Sleijfer DT, Lalisng RI, Bakker PJM, Mandjes I, Kooi M, de Vries EGE (1999) A multi-center prospective phase II study of highdose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10: 1467-1473
19. Saxman SB, Nichols CR, Einhorn LH (1994) Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 12: 1390-1393
20. Schmoll HJ, Beyer J (1998) Prognostic factors in metastatic germ cell tumors. Semin Oncol 25: 174-185